Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT‐0401 and REVERSE randomised clinical studies

BACKGROUND: The goal of hepatorenal syndrome type 1 (HRS‐1) treatment is to improve renal function. Terlipressin, a synthetic vasopressin analogue, is a systemic vasoconstrictor used for the treatment of HRS‐1, where it is available. AIM: To compare the efficacy of terlipressin plus albumin vs. plac...

Descripción completa

Detalles Bibliográficos
Autores principales: Sanyal, A. J., Boyer, T. D., Frederick, R. T., Wong, F., Rossaro, L., Araya, V., Vargas, H. E., Reddy, K. R., Pappas, S. C., Teuber, P., Escalante, S., Jamil, K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Reversal of Hepatorenal Syndrome
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5434950/
https://www.ncbi.nlm.nih.gov/pubmed/28370090
http://dx.doi.org/10.1111/apt.14052

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5434950/
https://www.ncbi.nlm.nih.gov/pubmed/28370090
http://dx.doi.org/10.1111/apt.14052

Ejemplares similares